Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.

Buckley NE. et al, (2016), Oncotarget, 7, 19884 - 19896

Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways

Psaila B. et al, (2016), Genome Biology

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.

Findlay JM. et al, (2016), Nature communications, 7, 11111 - 11111

Single cell RNA sequencing reveals molecular and functional platelet bias of aged hematopoietic stem cells

Nerlov C. et al, (2016), Nature Communications

The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.

Hopkins TG. et al, (2016), Nucleic Acids Res, 44, 1227 - 1246

Delayed oral toxicity from long term Vemurafenib therapy

Lloyd-Lavery A. et al, (2016)

Phase I Dose Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

Macaulay V., (2016), Clinical Cancer Research

Acute EBV masquerading as peripheral T-cell lymphoma.

Zhang X-Y. et al, (2016), BMJ Case Rep, 2016

A dynamic niche provides Kit ligand in a stage-specific manner to the earliest thymocyte progenitors

Buono M. et al, (2016), Nature Cell Biology

A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.

Blagden SP. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34

Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality.

Lord S. et al, (2016), Curr Drug Targets, 17, 1714 - 1727

Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis.

Findlay JM. et al, (2016), Dig Dis Sci, 61, 25 - 38

Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.

Malczewski A. et al, (2016), Cancer Med, 5, 17 - 23

SOCQER-2 Study: Preliminary analysis of multicentre recruitment after surgery in advanced ovarian cancer

Kumar S. et al, (2016), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 26, 832 - 833

Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.

Kaisaki PJ. et al, (2016), PLoS One, 11

Turning the concept of synthetic lethality on its head

Parkes EE. and Kennedy RD., (2016), TRANSLATIONAL CANCER RESEARCH, 5, S1145 - S1148

Window of opportunity studies: investigating the bioactivity of metformin in cancer

Lipplaa A. et al, (2015), Journal of Endocrinology, Diabetes and Obesity

A Potential Novel Application of Eltrombopag: A Combination Agent to Enhance Iron Chelation Therapy

Koumoutsea EV. et al, (2015), BLOOD, 126

Ezh2 and Runx1 Mutations Targeted to Early Lymphoid Progenitors Collaborate to Promote Early Thymic Progenitor Leukemia

Booth C. et al, (2015), BLOOD, 126

Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)

Mesa RA. et al, (2015), BLOOD, 126